Background Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID‐19)
affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of …

The immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical
modulators of immune activation. These pathways dampen the immune response by …

Simple Summary The use of immune checkpoint inhibitors (ICIs) to treat oncologic diseases
is progressively increasing. Computed tomography (CT) features of ICI therapy-related …

Identification of novel immune biomarkers to gauge the underlying pathology and severity of
COVID-19 has been difficult due to the lack of longitudinal studies. Here, we analyzed serum …

Background The association between immune checkpoint inhibitor (ICI) and outcomes of
cancer patients with coronavirus disease 2019 (COVID-19) infection has yet to be …

By the beginning of the global pandemic, SARS-CoV-2 infection has dramatically impacted
on oncology daily practice. In the current oncological landscape, where immunotherapy has …

Kidney function is affected in COVID-19, while kidney itself modulates the immune response.
Here, hypothesize if COVID-19 urine biomarkers level can assess immune activation vs …

Objectives To compare the radiological findings of immune checkpoint inhibitor-related
pneumonitis (IRP) and COVID-19 pneumonia, evaluating the potential of the CO-RADS …

Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events
(irAEs). The coronavirus disease 2019 (COVID-19) is associated with increased amounts of …

Simple Summary Patients with cancer who contract COVID-19 are very vulnerable to
increased complications and illness while actively being treated with chemotherapy or …